Brief: Cogent Biosciences Q4 Operating Expenses USD 99.493 Million
17/02/2026 13:00
Feb 17 (Reuters) - Cogent Biosciences Q4 income from operations USD -99.493 million. Q4 net income USD -102.492 million
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's